Program
vecuronium
Also written as “Vecuronium” and “vecuronium bromide (0.1mg/kg)”.
Its studies are mostly in Arrhythmias, Cardiac, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Merck | 30 open or running | phase 4since Nov 15, 2017 | May 14, 2007 | none ahead |
| Amckaus PTY | 11 open or running | phase 2since Apr 20, 2026 | Apr 20, 2026 | Jun 30, 2027phase 2 · NCT07595393 |
Also a collaborator on its studies: novotech-australia-pty-limited.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 14, 2007First study: phase 3 study in Anesthesia, GeneralNew to MerckMerck · NCT00473694 · 182 enrolled
- Oct 31, 2007Phase 2 study in Anesthesia, GeneralMerck · NCT00552617 · 100 enrolled
- Nov 15, 2017Phase 4 study in Arrhythmias, CardiacMerck · NCT03346057 · 344 enrolled · United States, Austria, Denmark and more
- Apr 20, 2026Amckaus PTY's first study: phase 2 study in Reversing Vecuronium-Induced Neuromuscular Blockade in Patients Undergoing General Anesthesia SurgeryNew to Amckaus PTYAmckaus PTY · NCT07595393 · 64 planned
Ahead
- Jun 30, 2027Primary completion: phase 2 study in Reversing Vecuronium-Induced Neuromuscular Blockade in Patients Undergoing General Anesthesia SurgeryAmckaus PTY · NCT07595393
TargetBeta
“Muscle-type nicotinic acetylcholine receptor antagonist”ChEMBL 37, by rule
Other programs on the same 5 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Rocuroniumrule | Merck | phase 4 | 11 |
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07595393Reversing Vecuronium-Induced Neuromuscular Blockade in Patients Undergoing General Anesthesia Surgery | 2 | Not yet recruiting | Amckaus PTY | Jun 30, 2027 | 64 |
| NCT03346057Arrhythmias, Cardiac · United States, Austria, Denmark and more | 4 | Completed | Merck | Sep 4, 2019 | 344 |
| NCT00552617Anesthesia, General | 2 | Completed | Merck | Aug 31, 2006 | 100 |
| NCT00473694Anesthesia, General | 3 | Completed | Merck | Nov 6, 2006 | 182 |
How it is read
Names in the registry
- “Vecuronium”, 2 entries
- “vecuronium bromide (0.1mg/kg)”, 1 entry
- “vecuronium”, 1 entry
Conditions, from the studies’ own filings
- Arrhythmias, Cardiac, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.